Survival Rate and Prognostic Factors of Endometrial Cancer Patients Treated in Ratchaburi Hospital
Keywords:
endometrial cancer, survival rates, prognostic factorsAbstract
Objective: Primary objective was to analyze the 5-year survival rate and secondary objective was to analyze prognostic factors among endometrial cancer patients at Ratchaburi Hospital.
Methods: This retrospective study included endometrial cancer patients diagnosed during the period January 1, 2009 to December 31, 2013 and followed up until the end of 2018. The clinico-pathological data of the patients were collected for evaluation. Kaplan-Meier estimates of survival and log-rank test were used to compare survival distributions between stages, histologic subtypes. Cox regression was used to estimate hazard ratios for significant prognostic factors.
Results: Fourty patients had diagnosis of endometrial cancer. The median age of the patients was 55.8 years . The age distribution varied from 38 to 73 years. It was found that 11 cases (27.5 %) had died and 29 cases (72.5 %) were still alive. The overall survival rate at 5 years was 82.5 %. The 5-year survival rates for stages IA, IB, II, and IIIC were 94.1, 83.3, 80, and 50 respectively. When analysis was conducted by stages combined into 2 groups: early (stages I and II) and late (stage III and IV), the 5-year survival rate for the early stage (88.2%) was higher than for the late stage (50%) (p=.030). In addition, when analysis was conducted by age groups, histologic subtypes, stages, residual tumor < 1cm (optimal surgery), lymph node status, and distant organ metastasis, the findings showed that the age groups affected patient survival rates. More than sixty-year-old patients showed the adjusted hazard ration were 14.78 (p=.008) compared with younger patients.
Conclusion : These findings indicate that early diagnosis and treatment increased overall survival rates and elderly patients should be followed up frequently.
References
2. Bernard WS, Christopher PW. World cancer report 2014.1sted.Lyon: the International Agency for Research on Cancer;2014.
3. สถาบันมะเร็งแห่งชาติ. หนังสือทะเบียนมะเร็งระดับโรงพยาบาล พ.ศ. 2560 Hospital-based cancer registry 2017. กรุงเทพฯ: กลุ่มงานเทคโนโลยีสารสนเทศ สถาบันมะเร็งแห่งชาติ; 2561.
4. ศิริวรรณ ตั้งจิตกมล. มะเร็งเยื่อบุโพรงมดลูก Endometrial cancer. กรุงเทพฯ: คณะแพทยศาสตร์วชิรพยาบาล มหาวิทยาลัยนวมินทราธิราช; 2559.
5. Bokhman JV. Two patho genetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1): 10-7.
6. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851-6.
7. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J GynaecolObstet. 2009; 105(2): 103-4.
8. ASTEC/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials), pooled trial results, systematic review, and meta-analysis. Lancet. 2009: 373(9658); 137-46.
9. Susumu N, Sagae S, Udagawa Y, et al. Japanese gynecologic oncology group. Randomized phase III trial of pelvis radiotherapy versus cisplatin- based combined chemotherapy in patients with intermediate and high-risk endometrial cancer. A Japanese gynecologic oncology group study. Gynecol Oncol. 2008: 108; 226-33.
10. Noone AM, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2015 [Internet] 2018 [cited 2019 Feb 5]. Available from: https://seer.cancer.gov/csr/1975_2015.
11. Lee NK, Cheung MK, Shin JY, et al. Prognostic factors for uterine cancer in reproductive aged women. ObstetGynecol. 2007;109(3):655-62.
12. Zaino RJ, Kurman RJ, Diana KL, et al. Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage—a Gynecologic Oncology Group study. Cancer. 1996;77(6):1115-21.
13. Okuma K, Yamashita H, Kawana K, et al. Advanced age is a significant determinant of poor prognosis in patients treated with surgery plus postoperative radiotherapy for endometrial cancer. J Obstet Gynaecol Res. 2010;36(4):757-63.
14.Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, et al. Endometrial cancer in Thai women: clinico-pathological presentation and survival. Asian Pac J Cancer Prev. 2010;11(5):1267-72.
15. American Cancer Society: Cancer Facts and Figures 2015 [Internet]. 2015 [cited 2019 Aug 1]. Available from: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acs [c-044552.pdf.
16. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26thAnnaul Report on the Results of Treatment in Gynecological Cancer. Int J GynaecolObstet. 2006; 95(Supp(1): S105-43.
17. Prueksaritanon N, Chantape W. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital. J Med Assoc Thai. 2016; 99 (Suppl. 2): S75-S83.
18. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 2013;129(2):277-84.
19. Wright JD, Lewin SN, BarrenaMedel NI, et al. Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome. Gynecol Oncol. 2011; 122(6): 69-74.
Downloads
Published
How to Cite
Issue
Section
License
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
